These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 2109379)

  • 1. In vivo cell activation following OKT3 administration. Systemic cytokine release and modulation by corticosteroids.
    Chatenoud L; Ferran C; Legendre C; Thouard I; Merite S; Reuter A; Gevaert Y; Kreis H; Franchimont P; Bach JF
    Transplantation; 1990 Apr; 49(4):697-702. PubMed ID: 2109379
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Corticosteroid inhibition of the OKT3-induced cytokine-related syndrome--dosage and kinetics prerequisites.
    Chatenoud L; Legendre C; Ferran C; Bach JF; Kreis H
    Transplantation; 1991 Feb; 51(2):334-8. PubMed ID: 1899732
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD3 antibody-induced IL-10 in renal allograft recipients: an in vivo and in vitro analysis.
    Herbelin A; Abramowicz D; de Groote D; Naret C; Kreis H; Bach JF; Goldman M; Chatenoud L
    Transplantation; 1999 Sep; 68(5):616-22. PubMed ID: 10507478
    [TBL] [Abstract][Full Text] [Related]  

  • 4. OKT3 first-dose reaction: association with T cell subsets and cytokine release.
    Gaston RS; Deierhoi MH; Patterson T; Prasthofer E; Julian BA; Barber WH; Laskow DA; Diethelm AG; Curtis JJ
    Kidney Int; 1991 Jan; 39(1):141-8. PubMed ID: 1900552
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A pilot trial of recombinant human interleukin-10 in kidney transplant recipients receiving OKT3 induction therapy.
    Wissing KM; Morelon E; Legendre C; De Pauw L; LeBeaut A; Grint P; Maniscalki M; Ickx B; Vereerstraeten P; Chatenoud L; Kreis H; Goldman M; Abramowicz D
    Transplantation; 1997 Oct; 64(7):999-1006. PubMed ID: 9381549
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Release of tumor necrosis factor, interleukin-2, and gamma-interferon in serum after injection of OKT3 monoclonal antibody in kidney transplant recipients.
    Abramowicz D; Schandene L; Goldman M; Crusiaux A; Vereerstraeten P; De Pauw L; Wybran J; Kinnaert P; Dupont E; Toussaint C
    Transplantation; 1989 Apr; 47(4):606-8. PubMed ID: 2523100
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [T lymphocyte activation induced in vivo by the first injection of OKT3 monoclonal antibodies].
    Chatenoud L; Ferran C; Reuter A; Legendre C; Gevaert Y; Kreis H; Franchimont P; Bach JF
    C R Acad Sci III; 1988; 307(19):833-6. PubMed ID: 3146414
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evidence that antihuman tumor necrosis factor monoclonal antibody prevents OKT3-induced acute syndrome.
    Charpentier B; Hiesse C; Lantz O; Ferran C; Stephens S; O'Shaugnessy D; Bodmer M; Benoit G; Bach JF; Chatenoud L
    Transplantation; 1992 Dec; 54(6):997-1002. PubMed ID: 1465794
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vivo soluble tumor necrosis factor receptor release in OKT3-treated patients. Differential regulation of TNF-sR55 and TNF-sR75.
    Herbelin A; Chatenoud L; Roux-Lombard P; De Groote D; Legendre C; Dayer JM; Descamps-Latscha B; Kreis H; Bach JF
    Transplantation; 1995 May; 59(10):1470-5. PubMed ID: 7770936
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pentoxifylline does not prevent the cytokine-induced first dose reaction following OKT3--a randomized, double-blind placebo-controlled study.
    Vincenti F; Danovitch GM; Neylan JF; Steiner RW; Everson MP; Gaston RS
    Transplantation; 1996 Feb; 61(4):573-7. PubMed ID: 8610383
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cascade modulation by anti-tumor necrosis factor monoclonal antibody of interferon-gamma, interleukin 3 and interleukin 6 release after triggering of the CD3/T cell receptor activation pathway.
    Ferran C; Dy M; Sheehan K; Schreiber R; Grau G; Bluestone J; Bach JF; Chatenoud L
    Eur J Immunol; 1991 Oct; 21(10):2349-53. PubMed ID: 1833202
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effects of oral pentoxifylline on the cytokine release syndrome during inductive OKT3.
    DeVault GA; Kohan DE; Nelson EW; Holman JM
    Transplantation; 1994 Feb; 57(4):532-40. PubMed ID: 8116037
    [TBL] [Abstract][Full Text] [Related]  

  • 13. OKT3 F(ab')2 fragments--retention of the immunosuppressive properties of whole antibody with marked reduction in T cell activation and lymphokine release.
    Woodle ES; Thistlethwaite JR; Ghobrial IA; Jolliffe LK; Stuart FP; Bluestone JA
    Transplantation; 1991 Aug; 52(2):354-60. PubMed ID: 1908148
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reduction of morbidity and cytokine release in anti-CD3 MoAb-treated mice by corticosteroids.
    Ferran C; Dy M; Merite S; Sheehan K; Schreiber R; Leboulenger F; Landais P; Bluestone J; Bach JF; Chatenoud L
    Transplantation; 1990 Oct; 50(4):642-8. PubMed ID: 1699310
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selective in vivo deletion of alloactivated TH1 cells by OKT3 monoclonal antibody in acute rejection.
    Reinke P; Schwinzer H; Höflich C; Ode-Hakim C; Döcke WD; Frei U; Volk HD
    Immunol Lett; 1997 Jun; 57(1-3):151-3. PubMed ID: 9232443
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of a single amino acid mutation on the activating and immunosuppressive properties of a "humanized" OKT3 monoclonal antibody.
    Alegre ML; Collins AM; Pulito VL; Brosius RA; Olson WC; Zivin RA; Knowles R; Thistlethwaite JR; Jolliffe LK; Bluestone JA
    J Immunol; 1992 Jun; 148(11):3461-8. PubMed ID: 1534096
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytokine profiles in early rejection following OKT3 treatment in liver transplant patients.
    Roayaie S; Sheiner PA; Emre S; Guy S; Schwartz ME; Boros P; Miller CM
    Mediators Inflamm; 2000; 9(3-4):141-6. PubMed ID: 11132770
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inter-mouse strain differences in the in vivo anti-CD3 induced cytokine release.
    Ferran C; Dy M; Sheehan K; Merite S; Schreiber R; Landais P; Grau G; Bluestone J; Bach JF; Chatenoud L
    Clin Exp Immunol; 1991 Dec; 86(3):537-43. PubMed ID: 1721015
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase IA/IB trial of anti-CD3 murine monoclonal antibody plus low-dose continuous-infusion interleukin-2 in advanced cancer patients.
    Sosman JA; Kefer C; Fisher RI; Jacobs CD; Pumfery P; Ellis TM
    J Immunother Emphasis Tumor Immunol; 1995 Apr; 17(3):171-80. PubMed ID: 7613643
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Acute clinical syndrome associated with OKT3 administration. Prevention by single injection of an anti-human TNF monoclonal antibody].
    Charpentier B; Hiesse C; Ferran C; Lantz O; Fries D; Bach JF; Chatenoud L
    Presse Med; 1991 Nov; 20(40):2009-11. PubMed ID: 1837113
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.